Search jobs
Eucrates Biomedical Acquisition Corp. Announces The Separate Trading Of Its Ordinary Shares And Redeemable Warrants
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Eucrates Biomedical Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced that holders of the units sold in the Company's initial public offering of 10,000,000 units, may elect to separately trade the ordinary shares and redeemable warrants included in the units. Those units not separated will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the symbol "EUCRU," and the ordinary shares and redeemable warrants that are separated will trade on the Nasdaq under the symbols "EUCR" and "EUCRW," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into ordinary shares and redeemable warrants.